by Fred Dumais | Sep 14, 2022 | News Release
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for ARDSSabizabulin also showed significant reduction of days in ICU, days...
by Fred Dumais | Sep 13, 2022 | News Release
Record revenues of $6.1 million in Q3-22, a 27% increase over Q2-22 Record Gross Margins of $2.2 million in Q3-22, up 34% over Q2-22Record YTD-22 revenues of $15.1 million, up 48% over YTD 2021Q4-22 projected revenues to exceed $11 millionXIIDRA®, SIMBRINZA® and...
by Fred Dumais | Sep 9, 2022 | News Release
MONTREAL, QUEBEC , September 9, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022...
by Fred Dumais | Aug 30, 2022 | News Release
Kyle Steiger appointed Senior Vice-President and Chief Commercial OfficerJean-François Fournier appointed new Business Unit Head – Ophthalmology MONTREAL, QUEBEC, August 30, 2022 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the...
by Fred Dumais | Aug 2, 2022 | News Release
Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand into Ophthalmology and Allergy Licensing transactions to more than double Valeo’s annual...
by Fred Dumais | Aug 2, 2022 | News Release
700,000 Canadians suffering from severe allergies Canadian epinephrine auto-injector market exceeds $80M annually ALLERJECT peak sales potential expected to exceed $25M annually MONTREAL, QUEBEC , August 2, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2)...
